

## **SYMPHORIA**

PRESENTS NATIONAL e-SYMPOSIUM ON

# **EMERGING TRENDS IN DRUG DISCOVERY AND DEVELOPMENT**

Thursday, 3<sup>rd</sup> March 2022 to Saturday, 5<sup>th</sup> March 2022



*For Delegates from*

- *Pharma Industry*
- *Entrepreneurs*
- *Academicians*
- *Research Scholars*



Organised by

St. John Institute of Pharmacy and Research

*NAAC Accredited with Grade B and CGPA 2.40 (2017-22)*

St. John Technical Campus, Vevoor, Manor Road, Palghar (E), Dist. Palghar - 401 404

[www.sjpr.edu.in](http://www.sjpr.edu.in)

**EMERGING TRENDS IN DRUG DISCOVERY AND DEVELOPMENT****St. John Institute of Pharmacy and Research, Palghar****ABOUT SJIPR**

St. John Institute of Pharmacy and Research (SJIPR) conducts the four-year full-time Bachelor of Pharmacy (B. Pharm.) program since 2008, two-year full-time Diploma in Pharmacy (D. Pharm.) from 2013 and has commenced the two-year full-time Master of Pharmacy (M. Pharm.) with specialization in Quality Assurance from 2018. The Institute is approved by AICTE, DTE (MS), PCI and affiliated to the MSBTE (D. Pharm.) and University of Mumbai (B. Pharm. & M. Pharm.). In its Decennial Academic Year, 2017-18, the Institute not only got accreditation from NAAC with CGPA 2.40 and Grade B, but the B. Pharm. Programme was also accredited by NBA. Located within a lush green campus in the serene and quiet ambiance of St. John Technical Campus at Vevoor, Palghar (E), the Institute has spacious classrooms, well equipped state-of-the-art laboratories with an advanced and well maintained Class 10000 aseptic area, well-stocked library and modern computer centre with digital library. With our team of qualified and dedicated faculty and trained technical and support staff we are proud to say that in this span of time we have achieved:

- Excellent results at Final Year B. Pharm Examinations
- Ranks at University of Mumbai (2012-13, 2013-14, 2014-15 and 2015-16)
- Grants received from University of Mumbai, AICTE-ISTE, AICTE- MODROBS
- Industry Interaction and training with Tata Consultancy Services, Lupin Limited, ACG, Neon Laboratories, GlaxoSmithKline, Cognizant, Ashish Lifesciences, Aurochem Pvt. Ltd, Impulse Pharma, Wockhardt Hospital, Karuna Hospital, Dr. ML Dhawale Hospital

**VISION OF THE C****Serving Humanity through Excellence in Pharmacy Education and Research****MISSION**

- To promote quality pharmacy education and training through innovative teaching-learning process
- To collaborate with industry to address challenges of quality and novel medicines
- To encourage innovation towards designing solutions to meet healthcare needs
- To contribute to the advancement of community pharmacy and public health
- To empower young minds with value based education, communication and entrepreneurial skills

**OUR QUALITY POLICY**

To deliver quality and value education, through training and innovative teaching learning process, to build young and aspiring Pharmacists





## ABOUT SYMPHORIA

**Symphoria** is derived from sympherin in Greek which means bringing together of reactants into the proper spatial relationship. As the name suggests several Technical Events are planned by the Internal Quality Assurance Cell (IQAC) and organized under **Symphoria** with an aim to associate Industry-Institute-Faculty-Student. Through a series of Guest Lectures by prominent resource persons from Industry, Industrial Internships and Visits, Poster Presentations, Debates and Quizzes, students are educated about the recent Research and Developments in the field of Pharmaceuticals and various Career Opportunities available also help a graduating student to identify his/her career path.

## SYMPOSIUM HIGHLIGHTS

In recent years, the Drug Discovery Industry has seen remarkable developments and rapid progress. The global market for drug discovery technologies should grow from \$69.8 billion in 2020 to \$110.4 billion by 2025 with a compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025. In addition, bioinformatics, cheminformatics, and molecular modeling are expected to reduce the annual cost of developing a new drug by 33% and the time it takes to discover a new drug by 30%. The outbreak of COVID-19 led to a temporary halt in clinical trials of drug discovery for several diseases as the healthcare sector, researchers, and academia focused on curtailing COVID-19. This symposium on **Emerging Trends in Drug Discovery and Development** aims to bring together leading industry professionals, scientists, researchers to exchange and share their knowledge and experiences on various aspects of the drug discovery process. It will provide an interdisciplinary platform for industry and academia to present and discuss the recent innovations, trends, and concerns as well as practical challenges encountered and solutions implemented in this field. The symposium will also throw light on the new and upcoming areas like Machine Learning and their applications in the drug discovery process. Overall, the participants will benefit with the sharing of information in the varied scientific disciplines implemented to address the numerous aspects and challenges encountered in drug discovery, design and development.

## SESSION DETAILS

## KEYNOTE ADDRESS

DR. AJIT NAIR

Chief Development Officer, Rhizen Pharmaceuticals AG

## Technical Session I

DR. PRAJAKT BARDE, MD

Medical Director

MedIndite Communications Pvt Ltd

## Technical Session III

DR. GIRINATH PILLAI

Director

Zastra Innovations Pvt. Ltd.

## Technical Session V

DR. VENKATESAN JAYAPRAKASH

Professor, Department of Pharmaceutical Sciences and  
Technology BIT, Mesra

## Technical Session II

MR. SACHIN MANGALVEDHEKAR

Senior General Manager

Clinical &amp; PV QA, Glenmark Pharmaceuticals

## Technical Session IV

PROF. D. VELMURUGAN

Former HOD, UGC BSR Faculty and  
Emeritus Professor, University of Madras

## Technical Session VI

DR. SHRIDHAR NARAYANAN

CEO and Founder, Foundation for Neglected Disease  
Research (FNDR)

**PATRONS**

**Mr. ALBERT W. D'SOUZA**  
Chairman, Aldel Education Trust

**Mrs. ELVINA D'SOUZA**  
Secretary, Aldel Education Trust

**CONVENER**

**Dr. SAVITA J. TAURO**  
Principal, SJIPR

**CO-ORDINATOR**

**Dr. BHARAT DHOKCHAWLE**  
Asso. Professor HOD, Dept. of Pharm. Chemistry, SJIPR

**ORGANIZING COMMITTEE**

**Mr. Prashant Chaturvedi**  
**Mrs. Deepali Nahar**  
**Mrs. Sahaya Nadar**  
**Mr. Ramesh Bhusal**  
**Ms. Ekta Patel**  
**Ms. Sayli Churi**

**REGISTRATION COMMITTEE**

*For queries related to registration please contact:*

**Mr. Tanavirsing Rajput: 9404143806**  
**Mrs. Saswati Panigrahi: 7894712913**  
**Mrs. Varsha Ghodke: 8788355086**  
**Ms. Apoorva More: 9665544609**

**REGISTRATION DETAILS**

- **NO REGISTRATION FEE**, however Registration is Mandatory.
- Once successfully registered, participants will receive confirmation through mail.
- E-Certificate will be issued to only those participants who attend all the sessions and submit the feedback form.

For enquiries - Email: [symphoria@sjpr.edu.in](mailto:symphoria@sjpr.edu.in)

**Registration Link/Form:** <https://forms.gle/MMRKFVYY2R24jsie7>

For further details please visit:- [www.sjpr.edu.in](http://www.sjpr.edu.in)

**SYMPHORIA 2022**  
**EMERGING TRENDS IN DRUG DISCOVERY AND**  
**DEVELOPMENT**  
**Symposium Agenda**

<b>Day 1: Thursday 3<sup>rd</sup> March 2022</b>	
<b>Inauguration</b> 10.30 AM – 11.15 AM	Introductory Address: <b>Dr. (Mrs.) Savita J. Tauro</b> Principal, St. John Institute of Pharmacy and Research.
Keynote Address 11:15 AM to 12:30 PM	Chief Guest <b>Dr. Ajit Nair</b> Chief Development Officer, Rhizen Pharmaceuticals AG <i>Keynote Address</i>
12:30 PM to 01:30 PM	LUNCH BREAK
<b>Technical Session I</b> 01.30 PM-03.00 PM	Dr Prajakt Barde, Medical Director, MedIndite Communications Pvt Ltd <i>Topic: Drug Development: Clinical Development Science Nuances and possible Solutions</i>
<b>Day 2: Friday 4<sup>th</sup> March 2022</b>	
<b>Technical Session II</b> 10.00 AM -11.30 AM	<b>Mr. Sachin Mangalvedhekar</b> Head - Clinical & PV QA, Glenmark Pharmaceuticals <i>Topic: Clinical Trials, Pharmacovigilance and Quality- from the Basics to Advanced</i>
<b>Technical Session III</b> 11.45 AM -01.15 PM	<b>Dr. Girinath Pillai</b> Director, Zastra Innovations Pvt. Ltd. <i>Topic: Role of Machine Learning and ADME in Lead optimisation</i>
1.15 PM -2.15 PM	Lunch Break
<b>Technical Session IV</b> 02.15 PM -03.30 PM	<b>Prof D Velmurugan</b> UGC Career Awardee Former HoD, UGC BSR Faculty and Emeritus Professor, CAS in Crystallography and Biophysics & Former Coordinator, Bioinformatics Infrastructure Facility, Funded by DBT University of Madras, Guindy Campus, Chennai -25. <i>Topic: Recent Trends in Herbal Based Drug Discovery</i>
<b>Day 3: Saturday 5<sup>th</sup> March 2022</b>	
<b>Technical Session V</b> 10.00 AM -11.30 AM	<b>Dr. Venkatesan Jayaprakash</b> Professor, Department of Pharmaceutical Sciences and Technology BIT, Mesra, Ranchi <i>Topic: Exploring conditionally essential targets for antitubercular drug discovery</i>
<b>Technical Session VI</b> 11.45 AM -01.15 PM	<b>Dr. Shridhar Narayanan</b> CEO and Founder, Foundation for Neglected Disease Research (FNDR) <i>Topic: Discovery of antitubercular drugs</i>
1.15 PM- 1.45 PM	Valedictory Function